MedTrace Logo

A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL

NCT01874288 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2020-11-24

Study results available
· View outcomes & findings →

Summary

This dose-escalation study is designed for determining the safety, tolerability, pharmacokinetics (PK), biological, and clinical activity of DI-Leu16-IL2 administered to participants with cluster of differentiation 20 (CD20) positive NHL that have failed standard rituximab-containing therapy.

Conditions

  • B-cell Non-Hodgkin Lymphoma

Interventions

DRUG

DI-Leu16-IL2

DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.

Sponsors & Collaborators

  • Alopexx Oncology, LLC

    lead INDUSTRY

Principal Investigators

  • Daniel Vlock, MD · Alopexx Oncology, LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-25
Primary Completion
2014-01-27
Completion
2016-11-16

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01874288 on ClinicalTrials.gov